TY - JOUR
T1 - Effect of oral and vaginal hormonal contraceptives on inflammatory blood biomarkers
AU - Divani, Afshin A.
AU - Luo, Xianghua
AU - Datta, Yvonne H.
AU - Flaherty, James D.
AU - Panoskaltsis-Mortari, Angela
N1 - Publisher Copyright:
© 2015 Afshin A. Divani et al.
PY - 2015
Y1 - 2015
N2 - The use of combined hormonal contraceptives has been reported to increase the level of C-reactive protein (CRP). We assessed the effect of hormonal contraceptive use on inflammatory cytokines including CRP, monocyte chemotactic protein-1, soluble tumor necrosis factor (sTNF), interleukin-6 (IL-6), and soluble CD40 ligand. We used 79 female subjects (19 to 30 years old) who were combined oral contraceptives users (n=29), combined vaginal contraceptive users (n=20), and nonusers (n=30) with CRP values of ≤1 (n=46) or ≥3 (n=33). Information on medical history, physical activities, and dietary and sleeping habits were collected. Both oral and vaginal contraceptive users had higher levels of CRP (P<0.0001), compared to nonusers. Only oral contraceptive users exhibited elevated sCD40L (P<0.01). When comparing the groups with CRP ≤ 1 and CRP ≥ 3, levels of IL-6 and sTNF-RI were positively correlated with CRP among oral contraceptive users. We did not observe the same elevation for other inflammatory biomarkers for the CRP ≥ 3 group among vaginal contraceptive users. The clear cause of elevation in CRP level due to the use of different hormonal contraceptive formulations and methods is not well understood. Longitudinal studies with larger sample size are required to better assess the true cause of CRP elevation among hormonal contraceptive users.
AB - The use of combined hormonal contraceptives has been reported to increase the level of C-reactive protein (CRP). We assessed the effect of hormonal contraceptive use on inflammatory cytokines including CRP, monocyte chemotactic protein-1, soluble tumor necrosis factor (sTNF), interleukin-6 (IL-6), and soluble CD40 ligand. We used 79 female subjects (19 to 30 years old) who were combined oral contraceptives users (n=29), combined vaginal contraceptive users (n=20), and nonusers (n=30) with CRP values of ≤1 (n=46) or ≥3 (n=33). Information on medical history, physical activities, and dietary and sleeping habits were collected. Both oral and vaginal contraceptive users had higher levels of CRP (P<0.0001), compared to nonusers. Only oral contraceptive users exhibited elevated sCD40L (P<0.01). When comparing the groups with CRP ≤ 1 and CRP ≥ 3, levels of IL-6 and sTNF-RI were positively correlated with CRP among oral contraceptive users. We did not observe the same elevation for other inflammatory biomarkers for the CRP ≥ 3 group among vaginal contraceptive users. The clear cause of elevation in CRP level due to the use of different hormonal contraceptive formulations and methods is not well understood. Longitudinal studies with larger sample size are required to better assess the true cause of CRP elevation among hormonal contraceptive users.
UR - http://www.scopus.com/inward/record.url?scp=84926374422&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84926374422&partnerID=8YFLogxK
U2 - 10.1155/2015/379501
DO - 10.1155/2015/379501
M3 - Article
C2 - 25861161
AN - SCOPUS:84926374422
SN - 0962-9351
VL - 2015
JO - Mediators of inflammation
JF - Mediators of inflammation
M1 - 379501
ER -